Morepen Laboratories Limited has informed the Exchange regarding a press release dated April 29, 2025, titled "Morepen to Launch Resmetirom- a New Drug for Fatty Liver".
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories has announced the launch of Resmetirom, a new drug aimed at treating fatty liver disease (MASH/NASH). The announcement is based on a press release dated April 29, 2025. Resmetirom is the first FDA-approved therapy for non-cirrhotic MASH with moderate-to-advanced liver fibrosis, marking a significant step for Morepen into a high-demand therapeutic segment. The launch positions the company in the specialty liver care market, which has limited treatment options globally. This move represents a strategic diversification beyond Morepen's traditional API and generic formulation businesses.
Positive for shareholders — entry into a novel, high-value therapeutic category could drive future revenue growth and improve margins, though near-term stock impact depends on pricing, distribution reach, and uptake. Investors should watch for follow-up announcements on launch timelines, partner details, and revenue contribution.